Featured Products & Services
-
Decentralized Clinical Trials: The Future Of Clinical Research
9/26/2022
Our integrated EDC platform, including eConsent, ePRO, RTSM, and DDC, is your gateway to decentralized trials.
-
Simulants: Unlock Insights And Accelerate Medical Breakthroughs
11/17/2023
Get an overview of this groundbreaking synthetic data product – uniquely derived from Medidata’s exclusive repository of global, standardized historical clinical trial data.
-
Medrio eConsent
10/5/2023
Flexible consent technology improves participant comprehension and process oversight. Learn how Medrio’s eConsent solution is empowering organizations to accelerate all aspects of the consent process.
-
Flexible Solutions To Facilitate Comprehension And Compliance
9/18/2024
Effective consent goes beyond signatures. Learn how to enhance participant understanding, streamlines document management, and improve workflow efficiency, to reduce errors and inspection risks.
-
ePRO For Oncology Studies
5/15/2024
Now introducing a customized ePRO solution designed specifically for oncology studies: a user-friendly app with a streamlined two-step onboarding process.
-
Unified, Integrated eClinical Research Solutions
1/16/2024
Facilitate efficient digitalization and optimization of clinical trials that meet the unique needs of small and mid-size biopharma organizations with the Signant SmartSignals Unified Platform.
-
Medrio eCOA/ePRO
10/10/2023
Learn how teams can enhance data quality, engagement, and retention through this affordable and patient-focused approach.
-
TrialKit eSource (Direct Data Capture)
6/6/2024
Gain confidence in your clinical research data with direct data capture (DDC).
-
ePRO: Capture Data At The True Source
9/25/2024
Learn more about the successful compliance rates achieved with Castor Connect, as well as how you can maximize your data capture, simplify site actions, and reduce your workload.
-
Hybrid eConsent: Remote And On-Site
3/21/2025
Studies show when participants are informed and comfortable with the consent process, they're more likely to comply with protocol, remain enrolled, and contribute to faster study deployment.